You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of EFTX-001 to target KRAS mutations in cancer

    SBC: Enfuego Therapeutics Inc.            Topic: 102

    Research Summary: The KRAS proto-oncogene is one of the most critical genes in cancer, yet it has also proven to be among the most elusive. Nearly all (98%) of KRAS missense mutations occur in codons 12 or 13, which leads to constitutive KRAS activation and promotion of numerous cancer hallmarks. Although kinase inhibitors have revolutionized treatment of some subsets of cancers driven by other mo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    Pulmonary arterial hypertension (PAH) affects ~15-50 individuals per million and claims ≥20,000 lives annually in the United States. It affects every ethnic group, race, age and gender, and devastates high-risk patients afflicted with HIV, systemic sclerosis, and sickle cell disease. The disease affects more women than men; adult PAH patients do not live more than five years after the diagnosis. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood.

    SBC: Redbud Labs, Inc.            Topic: 400

    ABSTRACT Microscale simulations have been applied to a number of complex microfluidic systems and biological applications, but existing methods are limited in the scale and scope of problems that are addressable. Thermodynamically constrained averaging theory (TCAT) is an established approach that can be used to formulate customized macroscale models that are consistent with microscale physics and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of gene therapy product for treating MPS IIIB

    SBC: NEUROGT, INC.            Topic: NINDS

    Project Summary NeuroGT, Inc is a new start-up company founded by Dr. Haiyan Fu, Associate professor in the Gene Therapy Center at University of North Carolina at Chapel Hill, with the mission of develop and commercialize effective gene therapy products to treat rare neurogenetic diseases in humans. The goal of this project is to develop an effective gene therapy product targeting the root cause f ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Prevention of corneal transplant rejection using AAV-HLA-G combination therapy

    SBC: Bedrock Therapeutics, Inc.            Topic: NEI

    Abstract Corneal blindness is a leading cause of global blindness, with allogeneic corneal transplantation (CT) being the most common form of tissue transplantation worldwide. Though approximately 180,000 CT surgeries are carried out each year, around 12.7 million are currently awaiting a donor cornea to undergo the operation. Still, CT surgery is accompanied by a high failure rate: as many as 20 ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis

    SBC: Arrevus, Inc.            Topic: NIAID

    PROJECT SUMMARYSepsis is a life-threatening syndrome that involves a systemic inflammatory response that is initiated by an infection. There are an estimated 1.5 million of cases annually in the US with 250,000 resulting in death. The number of cases and associated deaths is expected to increase given the rising at-risk population of elderly individuals and the compounding challenge of antibiotic ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Examination of a novel potential therapy for autonomic dysreflexia

    SBC: Dignify Therapeutics LLC            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections

    SBC: Synoxa Sciences, Inc            Topic: NIAID

    Project Summary Natural products have served as a productive source of drugs over the past decades and have represented, or been the inspiration for, a majority of antimicrobial compounds that have entered the clinic. The goal of this proposal is to develop novel antibacterial adjuvants based on the marine natural product synoxazolidinone B to treat Gram-positive orthopedic joint infections. These ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Chemically controlling chromatin to treat Friedriech's Ataxia

    SBC: Epigenos Bioscience, Inc.            Topic: NCATS

    We recently developed a technology that combines catalytically inactive dCas9 with bifunctional chemicals that link endogenous host cellular machinery to specific genes targeted with dCas9. We have demonstrated this technology can significantly increase gene expression at multiple endogenous mammalian genes in a chemically dependent manner. Here we propose to apply this technology to the mono-alle ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Non-Immunogenic PEG-like Conjugates of Uricase

    SBC: Gateway Bio, Inc.            Topic: NCATS

    ABSTRACT Covalent conjugation of therapeutic peptides and proteins with the “stealth” polymer poly(ethylene glycol) (PEG), termed PEGylation, is a widely used approach to increase the circulation half-life and stability of “biologics” —peptide, protein and oligonucleotide drugs— and to reduce their immunogenicity. However, recent studies show that PEG is itself immunogenic, as anti-PEG ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government